Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial by Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell

Get full text